(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer[U+05F3]s disease model mice by upregulating neprilysin expression

Experimental Cell Research

Volumn 334, Issue 1, 2015, Pages 136-145

  Chang, Xiang ^a   Rong, Cuiping ^a   Chen, Yunbo ^a,b   Yang, Cong ^a   Hu, Qian ^c   Mo, Yousheng ^a   Zhang, Chunxia ^a   Gu, Xiaoqiong ^d   Zhang, Lei ^a   He, Wenqing ^a   Cheng, Shuyi ^a,b   Hou, Xueqin ^a   Su, Ruyu ^a   Liu, Sijun ^a   Dun, Wenjun ^a   Wang, Qi ^a,b   Fang, Shuhuan ^a,b  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

Author keywords

( ) Epigallocatechin 3 gallate; Alzheimer U+05F3 s disease; Histone deacetylase inhibitor; Neprilysin; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; EPIGALLOCATECHIN GALLATE; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; CATECHIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHO CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOFLUORESCENCE; IN VITRO STUDY; MEMORY; MENTAL DETERIORATION; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SPATIAL LEARNING; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CHEMISTRY; COGNITION DISORDERS; CRICETULUS; DISEASE MODEL; DRUG EFFECTS; METABOLISM; STEREOISOMERISM;

MUS;

ALZHEIMER DISEASE; ANIMALS; CATECHIN; CELL PROLIFERATION; CELLS, CULTURED; CHO CELLS; COGNITION DISORDERS; CRICETULUS; DISEASE MODELS, ANIMAL; MICE; NEPRILYSIN; STEREOISOMERISM; UP-REGULATION;

EID: 84929276407     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.04.004     Document Type: Article

References (55)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer[U+05F3]s disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
2. Selkoe D.J. Toward a comprehensive theory for Alzheimer[U+05F3]s disease. Hypothesis: Alzheimer[U+05F3]s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. NY Acad. Sci. 2000, 924:17-25.
3. Hardy J.A., Higgins G.A. Alzheimer[U+05F3]s disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
4. Saido T.C. Alzheimer[U+05F3]s disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol. Aging 1998, 19:S69-S75.
5. Suh Y.H., Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer[U+05F3]s disease. Pharmacol. Rev. 2002, 54:469-525.
6. Hama E., Saido T.C. Etiology of sporadic Alzheimer[U+05F3]s disease: somatostatin, neprilysin, and amyloid beta peptide. Med. Hypotheses 2005, 65:498-500.
7. Carson J.A., Turner A.J. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?. J. Neurochem. 2002, 81:1-8.
8. Carson J.A., Ansai T., Awano S., Yu W., Takehara T., Turner A.J. Characterization of PgPepO, a bacterial homologue of endothelin-converting enzyme-1. Clin. Sci. (Lond.) 2002, 103(Suppl. 48):90S-93S.
9. Miners J.S., Baig S., Palmer J., Palmer L.E., Kehoe P.G., Love S. Abeta-degrading enzymes in Alzheimer[U+05F3]s disease. Brain Pathol. 2008, 18:240-252.
10. Miners J.S., van Helmond Z., Raiker M., Love S., Kehoe P.G. ACE variants and association with brain Abeta levels in Alzheimer[U+05F3]s disease. Am. J. Transl. Res. 2010, 3:73-80.
11. Miners J.S., Barua N., Kehoe P.G., Gill S., Love S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2011, 70:944-959.
12. Nalivaeva N.N., Fisk L.R., Belyaev N.D., Turner A.J. Amyloid-degrading enzymes as therapeutic targets in Alzheimer[U+05F3]s disease. Curr. Alzheimer Res. 2008, 5:212-224.
13. Hersh L.B., Rodgers D.W. Neprilysin and amyloid beta peptide degradation. Curr. Alzheimer Res. 2008, 5:225-231.
14. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., Saido T.C. Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292:1550-1552.
15. El-Amouri S.S., Zhu H., Yu J., Marr R., Verma I.M., Kindy M.S. Neprilysin: an enzyme candidate to slow the progression of Alzheimer[U+05F3]s disease. Am. J. Pathol. 2008, 172:1342-1354.
16. Balazs R., Vernon J., Hardy J. Epigenetic mechanisms in Alzheimer[U+05F3]s disease: progress but much to do. Neurobiol. Aging 2011, 32:1181-1187.
17. Wang J., Yu J.T., Tan M.S., Jiang T., Tan L. Epigenetic mechanisms in Alzheimer[U+05F3]s disease: implications for pathogenesis and therapy. Ageing Res. Rev. 2013, 12:1024-1041.
18. Adwan L., Zawia N.H. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer[U+05F3]s disease. Pharmacol. Ther. 2013, 139:41-50.
19. Chouliaras L., Rutten B.P., Kenis G., Peerbooms O., Visser P.J., Verhey F., van Os J., Steinbusch H.W., van den Hove D.L. Epigenetic regulation in the pathophysiology of Alzheimer[U+05F3]s disease. Prog. Neurobiol. 2010, 90:498-510.
20. Miller G. Epigenetics. A role for epigenetics in cognition. Science 2010, 329:27.
21. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., Yang C.S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003, 63:7563-7570.
22. Liu M., Chen F., Sha L., Wang S., Tao L., Yao L., He M., Yao Z., Liu H., Zhu Z., Zhang Z., Zheng Z., Sha X., Wei M. (-)-Epigallocatechin-3-gallate ameliorates learning and memory deficits by adjusting the balance of TrkA/p75 signaling in APP/PS1 transgenic mice. Mol. Neurobiol. 2013.
23. Biasibetti R., Tramontina A.C., Costa A.P., Dutra M.F., Quincozes-Santos A., Nardin P., Bernardi C.L., Wartchow K.M., Lunardi P.S., Goncalves C.A. Green tea (-)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. Behav. Brain Res. 2013, 236:186-193.
24. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., Ehrhart J., Townsend K., Zeng J., Morgan D., Hardy J., Town T., Tan J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 2005, 25:8807-8814.
25. Hu Q., Chang X., Yan R., Rong C., Yang C., Cheng S., Gu X., Yao H., Hou X., Mo Y., Zhao L., Chen Y., Dinlin X., Wang Q., Fang S. (-)-Epigallocatechin-3-gallate induces cancer cell apoptosis via acetylation of amyloid precursor protein. Med Oncol. 2015, 32:390.
26. Xia W., Zhang J., Kholodenko D., Citron M., Podlisny M.B., Teplow D.B., Haass C., Seubert P., Koo E.H., Selkoe D.J. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 1997, 272:7977-7982.
27. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
28. Xu Z., Fang S., Zuo Y., Zhang Y., Cheng R., Wang Q., Yang Z., Cai W., Ma J., Yang X., Gao G. Combination of pigment epithelium-derived factor with radiotherapy enhances the antitumor effects on nasopharyngeal carcinoma by downregulating vascular endothelial growth factor expression and angiogenesis. Cancer Sci. 2011, 102:1789-1798.
29. Fisk L., Nalivaeva N.N., Boyle J.P., Peers C.S., Turner A.J. Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes. Neurochem. Res. 2007, 32:1741-1748.
30. Grienberger C., Rochefort N.L., Adelsberger H., Henning H.A., Hill D.N., Reichwald J., Staufenbiel M., Konnerth A. Staged decline of neuronal function in vivo in an animal model of Alzheimer[U+05F3]s disease. Nat. Commun. 2012, 3:774.
31. Murrell J., Farlow M., Ghetti B., Benson M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer[U+05F3]s disease. Science 1991, 254:97-99.
32. Wei G., Chen Y.B., Chen D.F., Lai X.P., Liu D.H., Deng R.D., Zhou J.H., Zhang S.X., Li Y.W., Lii H., Liu L.F., Wang Q., Nie H. beta-Asarone inhibits neuronal apoptosis via the CaMKII/CREB/Bcl-2 signaling pathway in an in vitro model and AbetaPP/PS1 mice. J. Alzheimers Dis. 2013, 33:863-880.
33. Wang F., Chen H., Sun X. Age-related spatial cognitive impairment is correlated with a decrease in ChAT in the cerebral cortex, hippocampus and forebrain of SAMP8 mice. Neurosci. Lett. 2009, 454:212-217.
34. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
35. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O[U+05F3]Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
36. Dubrovskaia N.M., Nalivaeva N.N., Plesneva S.A., Feponova A.A., Turner A.J., Zhuravin I.A. Changes in the activity of amyloid-degrading metallopeptidases leads to disruption of memory in rats. Zh. Vyssh. Nerv. Deiat. Im. I. P. Pavlova 2009, 59:630-638.
37. Iijima-Ando K., Hearn S.A., Granger L., Shenton C., Gatt A., Chiang H.C., Hakker I., Zhong Y., Iijima K. Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. J. Biol. Chem. 2008, 283:19066-19076.
38. Yasojima K., Akiyama H., McGeer E.G., McGeer P.L. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 2001, 297:97-100.
39. Yasojima K., McGeer E.G., McGeer P.L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 2001, 919:115-121.
40. Ji Y., Permanne B., Sigurdsson E.M., Holtzman D.M., Wisniewski T. Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J. Alzheimers Dis. 2001, 3:23-30.
41. Zlokovic B.V., Ghiso J., Mackic J.B., McComb J.G., Weiss M.H., Frangione B. Blood-brain barrier transport of circulating Alzheimer[U+05F3]s amyloid beta. Biochem. Biophys. Res. Commun. 1993, 197:1034-1040.
42. Kim J., Castellano J.M., Jiang H., Basak J.M., Parsadanian M., Pham V., Mason S.M., Paul S.M., Holtzman D.M. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009, 64:632-644.
43. Vincent B., Smith J.D. Astrocytes down-regulate neuronal beta-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner. Eur. J. Neurosci. 2001, 14:256-266.
44. Walker J.R., Pacoma R., Watson J., Ou W., Alves J., Mason D.E., Peters E.C., Urbina H.D., Welzel G., Althage A., Liu B., Tuntland T., Jacobson L.H., Harris J.L., Schumacher A.M. Enhanced proteolytic clearance of plasma Abeta by peripherally administered neprilysin does not result in reduced levels of brain Abeta in mice. J. Neurosci. 2013, 33:2457-2464.
45. Daniel M., Tollefsbol T.O. Epigenetic linkage of aging, cancer and nutrition. J. Exp. Biol. 2015, 218:59-70.
46. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3:166-179.
47. Nalivaeva N.N., Belyaev N.D., Turner A.J. Sodium valproate: an old drug with new roles. Trends Pharmacol. Sci. 2009, 30:509-514.
48. Fischer A. HDAC inhibitors as therapy for neural disorders. Discovery of a new therapy. Pharm. Unserer Zeit 2010, 39:204-209.
49. Fischer A., Sananbenesi F., Mungenast A., Tsai L.H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 2010, 31:605-617.
50. Zhang L., Fang H., Xu W. Strategies in developing promising histone deacetylase inhibitors. Med. Res. Rev. 2010, 30:585-602.
51. Zhang H., Ma Q., Zhang Y.W., Xu H. Proteolytic processing of Alzheimer[U+05F3]s beta-amyloid precursor protein. J. Neurochem. 2012, 120(Suppl. 1):S9-S21.
52. Belyaev N.D., Nalivaeva N.N., Makova N.Z., Turner A.J. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 2009, 10:94-100.
53. Grimm M.O., Mett J., Stahlmann C.P., Haupenthal V.J., Zimmer V.C., Hartmann T. Neprilysin and Abeta clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer[U+05F3]s disease. Front. Aging Neurosci. 2013, 5:98.
54. Wang Z., Yang D., Zhang X., Li T., Li J., Tang Y., Le W Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PLoS One 2011, 6:e19229.
55. Wang Z., Zhang X.J., Li T., Li J., Tang Y., Le W Valproic acid reduces neuritic plaque formation and improves learning deficits in APP /PS1 transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin. CNS Neurosci. Ther. 2014, 20(3):209-217.